Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 12, 2020
Daily News
August 12, 2020
- Fujifilm-Sponsored Avigan Trial to Complete Enrollment on Aug. 16
August 12, 2020
- Biosimilars Showing Accelerated Uptick in Japan, Doctor Fee Incentive as Tailwind
August 12, 2020
- 2 Employees Infected with Coronavirus: Pfizer Japan
August 12, 2020
- Denka to Launch Rapid Antigen Test Kit for COVID-19 on August 13
August 12, 2020
- Xarelto OD Tablets Approved, Specially Developed for Japan: Bayer
August 12, 2020
- Taiho Confirms COVID-19 Cluster at Its Training Center, 8 Test Positive
August 12, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…